13 To investigate further the relations between myasthenia gravis, the thymus and autoimmunity ... possible that a cellular hypersensitivity mechanism plays a part in the pathogenesis.

Thymectomy is surgical removal of the thymus gland. It is not usually used to treat active MG but is believed to improve long-term outcome. 4 Removal of the thymus is indicated for patients with any ...

Researchers are also looking into the possible benefits of B-cell depletion treatments, which may play important roles in the underlying mechanisms of myasthenia gravis. B cells are a type of ...

The development of myasthenia gravis ten years after detection of thymoma 18 and four and a half years after thymectomy has been documented. 19 Hence, the patients described above will be followed ...

Efgartigimod showed sustained improvement in patients with generalized myasthenia gravis (gMG) and AChR autoantibodies, affirming its safety and efficacy in the ADAPT trial and extension.

Myasthenia gravis (MG) should be subgrouped into early-onset, late-onset, thymoma, ocular, anti-MuSK, anti-LRP4 and antibody-negative MG. MG has a prevalence of 140 per million, and an annual ...

Myasthenia Gravis is one such condition, where simple actions like keeping your eyes open, swallowing, or even taking a deep breath can feel like a challenge. The good news is that with the right ...

In 2024, the field of myasthenia gravis (MG) saw many developments from clinical trials of new treatments, including batoclimab, which have shown promise in improving patient outcomes, as well as ...